Cannabidiol is the active ingredient in CBD vape juice and CBD oil and is one of the 85 documented active cannabinoid ingredients contained in cannabis. CBD is a major phytocannabinoid and it makes up 40% of extracts from the cannabis plant. Currently, CBD Eliquid and CBD oil are the point of interest for scientists and professionals in medical circles since it has been noted to possess therapeutic properties. It has been demonstrated to significantly reduce tumor size, pacify epileptic seizures and ease pains especially of a chronic nature without the psychotropic effects of tetrahydrocannabinol (THC), another derivative from the same plant.
PHYSIOLOGICAL EFFECTS OF CBD OIL AND CBD ELIQUID
Generally CBD displays no toxicity in the human body and has no significant physiological effects. CBD when administered as CBD oil or CBD eliquid via various routes of administration has been shown to be quite
When administered in a wide variety of dosage levels, CBD has been shown to have no effect on the blood oxygen and carbon dioxide levels, blood sugar levels, heart rate, overall body temperature and hematocrit levels. CBD does not alter the levels of essential elements such as sodium and potassium levels in the human
Conclusive findings based on comprehensive studies carried out on the physiological effects of CBD indicate that it has no notable effects on pH blood plasma levels, arterial blood gas tensions, mean blood pressure or respiratory volume. In this regard, CBD administered as CBD oil or CBD eliquid does not affect human body ventilation parameters.
CBD does not stimulate the intake of food, nor does it stimulate the appetite in the human body. It does not cause any impairment in motor function and has no negative effect on the development of human embryonic cells.
NEUROLOGICAL EFFECTS OF CBD OIL AND CBD ELIQUID ON HUMAN BODY NERVOUS SYSTEM
CBD has been shown to have significant anti psychotic effects though the findings are based on an inconclusive study from a Cochrane Review carried out in 2014. These effects may level out the psychotomimetic effects of THC which are usually exhibited by patients with latent schizophrenia. These psychotomimetic effects are typically characterized by signs and symptoms of psychosis which include episodes of delusion or delirium in schizophrenic patients. It has been elucidated that CBD tends to have a stabilizing effect on N-Methyl D Aspartic acid (NMDA) receptor pathways in the human brain neural network and in this way, it significantly reduces symptoms associated with schizophrenia. These NMDA pathways are shared with other neurotransmitters like Gamma amino butyric acid(GABA) and norepinephrine.
The therapeutic effects of CBD as an antidepressant, neuroprotector and anxiolytic may be attributed to its action as a 5-HT 1A receptor partial agonist.
EFFECTS OF CBD OIL AND CBD ELIQUID ON THE HUMAN GLANDULAR SYSTEM
The human body endocannabinoid system is an internal regulatory system which regulates the body’s internal homeostatic environment which includes the growth and differentiation of cutaneous cells. CBD has been demonstrated to be a highly effective sebostatic agent and it also exerts remarkable anti-inflammatory properties. The combination of CBDs lipostatic, antiproloferative and anti-inflammatory effects display its potential as a therapeutic agent in the treatment of acne vulgaris, a human skin disease that affects millions of people worldwide.
CBD has a very low affinity for cannabinoid receptors type 1 and 2 and it tends to be an antagonist of their receptor agonist. This may result in an increase in receptor density and consequently the potentiating of the effects of THC.
Dravet’s Syndrome and the Use of CBD in Its Treatment
Dravet’s Syndrome is a rare form of one of the worst types of intractable epilepsy. It usually begins in the early stages of infancy and during the second year of life, other forms of epileptic seizures begin to emerge. In the recent past, a lot of interest has been generated by the positive therapeutic effects of CBD in the treatment of Dravet’s syndrome. GW Pharmaceuticals is marketing CBD under the trade name Epidiolex and is currently awaiting the Food and Drug Administration’s (FDA) approval in the United States of America.
Other Legal CBD Drug Formulations
During the year 2005, Nabiximols, a drug marketed under the trade name Sativex was approved to alleviate pains associated with multiple sclerosis. It is meant for oral administration as an aerosolized mist and contains almost an equal ratio of CBD and THC. In the United Kingdom, CBD, in combination with 9 Delta-THC is available as a prescription drug for the treatment of severe spasticity associated with multiple sclerosis.